Astellas Collaborates with KaliVir to Develop and Commercialize VET2-L2
Shots: KaliVir to receive $56M as upfront & other payments supporting the research & preclinical activities of VET2-L2 & is eligible to receive $307M & $271M as development, regulatory & commercialization for VET2-L2 & second product, respectively along with royalties on sales of each licensed… Read More »Astellas Collaborates with KaliVir to Develop and Commercialize VET2-L2